Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Eltrombopag for PGF and Aplastic Anemia
NCT06607367Phase 2Not yet recruiting
- Sponsor
- Melbourne Health
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib, eltrombopag in poor graft function (PGF), aplastic anemia, sponsored by Melbourne Health. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
ruxolitinibeltrombopag
03
Conditions
poor graft function (PGF)aplastic anemia
Beyond the preview
Go deeper on NCT06607367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06607367.